InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
82.36
(
0.46%
)
Bitcoin
68,515.14
(
0.01%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: mejs post# 20695

Monday, 07/23/2012 7:23:53 AM

Monday, July 23, 2012 7:23:53 AM

Post# of 80490

ARIA is going to look very attractive to NVS

Uhmm, no, not because of this, it isn't. It just means that NVS has a blockbuster drug on it's hands with Affinitor. They hardly need to acquire ridaforolimus for competitive reasons, lol. The simple fact is that NVS has gleevec and tasigna in cml, ldk378 in alk, and affinitor in the mTor space. Hate to burst your "buyout bubble" but NVS, imo, is one of the companies likely to be LEAST interested in acquiring Ariad.

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up